[99mTc]Tc-iPSMA SPECT/CT as an alternative to PET imaging for decision making in prostate cancer patients. PREP registry: Key findings. Total (n=4135) Cohort 1 (n=255): BF within 3 months from RP and ...

Adding 6 months of neoadjuvant deprivation therapy (NADT) doesn’t seem to add any benefit for patients with intermediate-risk ...

Initial report of a randomized trial of post-prostatectomy prostate cancer radiotherapy using either fluciclovine (18F) or PSMA (68Ga) PET/CT for target dose-escalation. This is an ASCO Meeting ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Glenn Bauman discussing a prospective ...

Gozetotide binds to the cancer cells with prostate-specific membrane antigen (PSMA) on their surface, making them visible ...

Telix Pharmaceuticals has announced that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved the ...

UK MHRA grants marketing authorization to Telix’s prostate cancer PET imaging agent, Illuccix: Melbourne, Australia Friday, February 14, 2025, 10:00 Hrs [IST] Telix, a commercia ...

PSMA-PET imaging [2] represents a major advancement in prostate cancer management, largely replacing conventional imaging methods (bone scan, CT [3] scan) as the standard of care after initial ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Radium-223 is an alpha-emitting radiopharmaceutical that accumulates in areas of high bone turnover and has demonstrated a survival benefit in metastatic prostate cancer, 1 but its benefits as a ...

Telix Pharmaceuticals Ltd.’s prostate cancer PET imaging agent Illuccix has been approved by the Danish Medicines Agency.

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that its prostate cancer PET[1] imaging agent Illuccix® ...